return equiti ttm
quarter initi guidanc
updat estim iqvia follow fourth-quart earn releas
wednesday morn februari summar increas adjust
ep estim cent quarter result strong better-than-expect
revenu driven three segment margin expect
although sequenti rate increas clearli slow initi
revenu guidanc consensu previou expect ep
guidanc previou estim line consensu result
increas revenu ep target manag comment give
us confid execut well gain commerci momentum
technolog cro busi combin favor demand backdrop
compani appear well posit double-digit earn growth year
briefli review iqv fourth quarter result expect top
bottom line million respect book well
expectationsund quarterli book-to-bil ratio time versu
typic time estim net award year-ago level organ
revenu growth increas sequenti despit
headwind higher pass-through revenu year ago expect full-
year step-up organ growth ds segment organ growth
technolog analyt solut slightli third
quarter contract sale medic solut improv sequenti growth
organ basi compar illustr exhibit iqv consolid
organ revenu growth best seen sinc merger complet
indic view compani regain share cro space also
gain traction new technolog offer
increas revenu estim million billion
organ constant currenc increas ep estim
expect underli organ growth technolog analyt solut
segment roughli segment expect
organ revenu growth unchang addit model basi point
consolid ebitda margin expans compar basi point previous
assum longer term greater portion ep growth come top-lin growth
rather margin leverag get beyond period merger-rel
synergi captur maintain outperform rate view current rel
valuat reason consid improv momentum technolog
iqvia integr inform technology-en healthcar servic provid annual revenu
base billion form merger quintil im health compani employ
roughli employe oper countri compani world lead provid
pharmaceut sale prescript data leader outsourc drug develop commerci
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
exhibit iqvia estim consolid organ growth present
segment observ expect
technolog analyt solut increas organ constant currenc basi quarter
compar target total revenu segment beat model million driven mainli stronger-
than-expect organ growth manag commentari suggest better-than-expect growth driven strong
perform compani real-world evid new technolog product oce platform
model organ growth slightli previous
 increas organ constant currenc basi quarter inclus lower pass-through
revenu target manag note headwind smaller pass-through
revenuesan artifact convers standardreduc organ growth basi point compar
basi point third quarter impli underli organ growth close period
look pass-through acceler basi point third quarter compani gener
net book-to-bil ratio roughli quarter ratio year-over-year backlog growth
inclus larg cancel discuss first-quart call metric
manag commentari add comfort organ revenu growth rd segment inch higher next year
addit spend environ appear healthi emerg biotech strategi appear
work well suggest busi gener high-single-digit growth
coronaviru manag indic includ guidanc expect million revenu impact
coronaviru first quarter hit ds segment model organ growth
 ds unchang would without first-quart headwind china
contract sale medic solut increas constant currenc basi fourth quarter result
surpass expect million third quarter csm segment gener organ
growth past three year model segment flat busi longer appear
deterior asset continu view non-cor busi thu would assum eventu
increas revenu estim million billion increas ep target
expect organ revenu growth basi point ebitda margin leverag
ad ep target higher start point unchang organ revenu growth
ebitda margin assumpt versu previous better reflect higher invest spend
xxsourc compani report william blair william blair
valuat stock thought
trade time updat ep target compar three-year averag multipl
time current peer multipl time maintain outperform rate given encourag sign
consist good book earli traction oceboth drive revenu
acceler updat model iqvia follow exhibit
view follow key risk iqvia next three five year slowdown spend
environ due lower end-market price exogen factor materi reduct amount
biotech fund increas competit price pressur clinic cro industri
exhibit updat iqvia hold incom statement summari
gener administr amort incom includ option beg incom expens tax investe non-controlling interests/minor incom item net incom excl non-recurring item incl option beg averag share outstand averag share outstand analysi gross profit beg beg rate revenu begin excl foreign exchang effect pro forma beg organ pro forma beg incom excl non-recur excl non-recur item incl blair compani estimatesourc compani report william blair compani llc estim import disclosur
